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Summary 
Objective: To perform a review of methods in clinical trials of hand OA and outline a set of guidelines. 
Methods: Methods related to assessing treatment in hand OA were classified as those obtaining general consensus and those on which 
there was disagreement and need for further work. 
Results: It was agreed that criteria validated for trials in knee and hip OA must be re-evaluated for hand OA; and that populations tudied, 
trial parameters and evaluation tools should meet criteria established herein. Consensus was not reached or further work is required 
regarding functional index, daily or weekly questionnaire, hand(s) taken into account, scoring system and consideration of aesthetic damage. 
Conclusion: New therapeutic trials are needed in hand OA. Guidelines for future trials are given. © 2000 OsteoArthritis Research Society 
International 
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Introduction 
There is a consensus on the existence of methodological 
problems that cast doubt on the reliability of 25 previously 
published trials in hand osteoarthritis (OA). Among such 
problems are absence of controls, limited numbers of 
patients studied and lack of precise definitions of hand OA 
and of inclusion and efficacy criteria 1 (and see the paper in 
this issue by O. Mejjad et al.). This is particularly true for 
studies of symptomatic slow-acting drugs in hand OA 
(Sy-SADOA). 1 New trials based on modern, consensual 
methodology are therefore required in hand OA. 
Points meeting agreement 
CATEGORIES OF DRUGS 
As for any OA localization, two categories of drugs 
should be distinguished: symptomatic fast-acting drugs 
(Sy-FADOA) or slow-acting drugs (Sy-SADOA) and 
structure-modifying drugs (SMOAD) which are considered 
to slow, stop or reverse the anatomical progression of the 
disease. 
CRITERIA FOR THERAPEUTIC TRIALS 
Randomized, placebo controlled, double-blind trials are 
the first step required, 2'3 but they must be based on 
validated criteria. The International Consensus Conference 
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for O,~ defined criteria for therapeutic trials in knee and hip 
OA. 2 It was agreed, however, that hand OA is not simply 
another localization of OA, comparable to OA of the knee or 
hip, since its clinical course is characterized by multiple 
joint involvement and disease exacerbations that differ from 
those of knee and hip OA. 4 
Thus the criteria validated for therapeutic trials per- 
formed in knee and hip OA need to be re-evaluated 
for hand OA, especially before trials of slow-acting 
symptomatic drugs and/or structure-modifying drugs are 
performed. 
POPULATIONS TO BE INCLUDED IN THE TRIALS 
Patients included should fulfill the ACR criteria for hand 
OA and features of hand OA should be demonstrated on 
X-ray examination, s Definition of radiographic hand OA is 
discussed in this issue of the journal. Radiographic evi- 
dence of osteophyte and/or joint space narrowing on inter- 
phalangeal (IP) joints or thumb base and/or Heberden's 
nodes or Bouchard's nodes should be demonstrated on 
recent (within 3 months) standard X-rays. 6 Exclusion cri- 
teria should include other rheumatic diseases involving the 
hands (chondrocalcinosis, psoriatic arthritis, hemochroma- 
tosis, secondary osteoarthritis) as well as all active dis- 
eases of the hands such as tendinitis, post-fracture pain, 
scarring and neurological diseasesZ 
INCLUSION CRITERIA FOR THE TRIALS OF DRUGS ACTING ON 
SYMPTOMS 
For Sy-FADOA and Sy-SADOA, hand OA should be 
symptomatic, with pain intensity rated on a visual analog 
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scale (VAS) at 30 mm or higher for at least one joint 
showing radiological changes. Symptoms constitute the 
primary criterion for study inclusion, irrespective of 
the degree of radiological involvement. Before patient inclu- 
sion, the duration of symptoms should be at least 1 week. 
There is no need to define more precisely the presence or 
absence of a flare. A score of at least 5-6 points on 
Dreiser's functional index for hand OA may be an alterna- 
tive Or additive criterion for inclusion, a A minimum baseline 
description of the disease should compose part of the 
study. 7 
WASH-OUT PERIOD 
For Sy-FADOA a wash-out period (NSAIDs and anal- 
gesics) should be required, while for Sy-SADOA, NSAIDs 
and analgesics can be allowed and their intake used as a 
secondary criterion of efficacy. 
DURATION OF THE TRIAL 
Concerning the Sy-FADOA, because the clinical course 
may spontaneously fluctuate during the trial (regardless of 
any therapeutic effect), increasing the duration of the 
trial may be suggested. However, it is impossible to 
define the optimum duration of such a trial: 2 weeks, 
1 month, 2 months, more than 2 months? Thus, there 
was a consensus on no fixed recommendation con- 
cerning the duration of a trial. For FADOA a duration of 
2-4 weeks appears sufficient. The risk/benefit ratio of 
FADOA such as NSAIDs should always be kept in mind 
in long-term trials. However, the trial duration might be 
safely increased for NSAIDs with a specific Cox-2 inhibition 
profile. 
For slow-acting drugs, Sy-SADOA, the interval before 
efficacy varies from a few weeks to 2-3 months with a 
persistent effect lasting up to 3 months after cessation 
of treatment. Therefore, for Sy-SADOA, a minimum of 
4 months' duration and a follow-up of 3 months after 
cessation of treatment should be recommendedZ 
INCLUSION OF THE THUMB BASE (FIRST CMC JOINT) AND 
INTERPHALANGEAL (IP) JOINTS IN THE SAME TRIAL 
Inclusion of these joints in the same trial is a difficult 
issue since these two Iocalizations of hand OA represent 
two different entities, differing in daily pain, in clinical course 
and in functional impairment. 9,1° At best, trials should 
include only patients with first CMC joint involvement or 
with only IP joint involvement (at least two joints affected). 
However, both CMC1 and IP joints may be symptomatic at 
the beginning of the trial or either may become sympto- 
matic during the trial. Therefore, the notion of flexibility with 
special means of evaluating the most painful joints needs to 
be introduced. Follow-up should focus on the most painful 
joints. 
PRIMARY EVALUATION TOOLS 
VAS for pain as the primary criterion, and as secondary 
criteria, functional indices for hand OA (Dreiser or Auscan) 
and overall assessment of the disease by the patient and 
the physician (taking into account all kinds of discomfort, 
including aesthetic prejudice) should be considered as 
primary evaluation tools. 
For Sy-SADOA, reduction in symptomatic fast-acting 
drug intake is an important parameter in such trials. Other 
criteria may be included, such as pain on lateral pressure of 
IP joints or measurement of grip strength. 
SPECIAL CRITERIA FOR SMOAD 
Contrary to fast- or slow-acting Sy-DOA, the primary 
criterion for SMOAD is not the presence of symptoms but 
the degree of structural abnormality on plain radiographs. 
Involvement of at least one first CMC joint or two IP joints 
should be required. Joint destruction should not be too 
advanced, since quantification of radiological progression 
would be difficult in cases with obliteration of the whole joint 
space width, erosions and subchondral bone sclerosis. 
Less than 50% of IP joints should be involved. For patients 
with painful hand OA, pain should be evaluated on long- 
term follow-up. It is useful to know whether change in pain 
correlates with anatomical changes. 
X-rays should be performed every year. A duration of 
at least 2 years appears minimal to detect radiographic 
changes. 
Points of disagreement or requiring further work 
FUNCTIONAL INDEX 
Dreiser's functional index is easily and quickly com- 
pleted. 8 Bellamy's index (AUSCAN) is today available only 
by request to the author. However, neither of them differ- 
entiates the first CMC joint from IP joints in terms of 
functional impairment; therefore, it may be useful to design 
and validate indices that better differentiate the first CMC 
joint function from function related to IP joint involvement. 
The sensitivity to change of these indices needs to be 
validated in long-term trials. 
PATIENT FOLLOW-UP: DAILY OR WEEKLY QUESTIONNAIRE? 
A daily questionnaire for hand OA may better detect 
variations in pain and functional impairment han one that is 
completed weekly. It may also have the advantage of 
indicating on a daily basis which joints are the most painful. 
However, in long-term trials compliance with such a ques- 
tionnaire may entail additional difficulty. Thus there is a 
need to compare daily and weekly self-administered ques- 
tionnaires to follow the presence_of pain over time in order 
to decide whether a daily or a weekly questionnaire would 
be the most appropriate. 
TAKING INTO ACCOUNT ONE HAND, BOTH HANDS, OR ONLY THE 
DOMINANT HAND 
A special tool to evaluate the most painful joints is 
recommended. However, predominant involvement of the 
dominant hand may influence the score of the functional 
index. 
SCORING SYSTEM TO FOLLOW X-RAY CHANGES IN SMOAD TRIALS 
The scoring system for changes in SMOAD trials was 
discussed in the radiographic portion of this workshop. 
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There is no consensus on the choice of the scoring system. 
There are two parameters for evaluating progression: the 
number of newly affected joints and the progression in each 
initially affected joint. Each parameter may be counted 
separately or they may be totaled in a composite scoring 
system. 
However, concerning the count of newly affected joints, a 
consensus is needed to define the earliest radiographic 
feature of hand OA: osteophyte, joint space narrowing, 
subchondral sclerosis, or all three. 11 / 
On the other hand, concerning the assessment of pro- 
gression in affected joints, the Kellgren-Lawrence classifi- 
cation (passage from one stage to another), the scoring 
system of Buckland-Wright (number and size of osteo- 
phytes), the scoring system of Kallman (composite index), 
and the scoring system of Verbruggen (based on change 
from joint space narrowing to an erosive form) should be 
compared in terms of precision, sensitivity to change over 
time and clinical relevance. 12-15 We need to determine 
intra- and inter-observer eproducibility in reading for each 
of these scoring systems. 
AESTHETIC DAMAGE 
Some women consult only because of aesthetic con- 
cerns in the absence of pain or dysfunction. This problem is 
usually not taken into account in clinical trials. However, it 
appears relevant to re-evaluate the trials with SMOAD in 
light of this aesthetic factor. Could it be useful to conduct 
long-term trials with SMOAD in order to prevent articular 
destruction leading to unaesthetic deformations? 
Conclusion and guidelines for future therapeutic 
trials in hand OA 
There is obviously a need to conduct new therapeutic 
trials in hand OA for both classes of drugs: fast- and 
slow-acting drugs for symptoms and structure-modifying 
drugs. 
For symptomatic-acting drugs, the main criterion for 
inclusion should be the presence of symptoms. It appears 
important to differentiate the first CMC joint from involve- 
ment of IP joints. This underlines the need to validate 
specific indexes for each of them. Symptomatic patients 
(whatever their radiographic severity) could be included in 
trials evaluating symptom-modifying drugs. There are no 
precise guidelines concerning the duration of such trials for 
fast-acting drugs, while for slow acting-symptomatic drugs 
a minimum of 4 months' duration and an additional 
follow-up of 3 months should be recommended. 
For SMOAD, a trial duration of at least 2 years with 
radiographs at yearly intervals is required. The primary 
criterion for inclusion should be the radiographic stage of 
OA (<50% of joints involved and exclusion of joints with 
end-stage radiological appearance), irrespective of symp- 
toms. Concerning trials of SMOAD, the aesthetic damage 
should be assessed, since this is a major concern for 
patients. 
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